Kenvue Inc. (NYSE:KVUE) Given Average Rating of “Hold” by Analysts

Kenvue Inc. (NYSE:KVUE) has been given a consensus rating of “Hold” by the sixteen ratings firms that are currently covering the company, Marketbeat reports. Thirteen investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $19.5833.

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Canaccord Genuity Group lifted their price objective on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. Citigroup upped their target price on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. Finally, Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $23.00 to $18.00 in a research report on Friday, January 30th.

Kenvue Stock Performance

Shares of KVUE stock opened at $17.45 on Friday. The firm has a market capitalization of $33.45 billion, a price-to-earnings ratio of 22.66, a PEG ratio of 3.98 and a beta of 0.51. The stock has a fifty day moving average of $17.96 and a 200 day moving average of $17.24. Kenvue has a 52 week low of $14.02 and a 52 week high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $3.68 billion. During the same period in the previous year, the firm earned $0.26 EPS. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, research analysts expect that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date of this dividend was Wednesday, February 11th. Kenvue’s dividend payout ratio is presently 107.79%.

Hedge Funds Weigh In On Kenvue

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Salomon & Ludwin LLC bought a new stake in shares of Kenvue during the 3rd quarter valued at $25,000. NBT Bank N A NY increased its stake in shares of Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after acquiring an additional 1,006 shares in the last quarter. Cornerstone Planning Group LLC lifted its position in Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after acquiring an additional 1,361 shares during the period. Physician Wealth Advisors Inc. lifted its position in Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares during the period. Finally, Elyxium Wealth LLC bought a new stake in Kenvue during the fourth quarter worth about $26,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.